Value Creation with Healthcare Products & Services

The JVCKENWOOD Group develops products for the healthcare industry by making use of the unique expertise that we possess in image and video processing technologies and in optical disk technologies. Seeking to ensure that as many people as possible receive appropriate medical services, we assist those working at the frontlines of medicine by developing medical image display monitors with high diagnostic interpretation efficiency as well as a particle (exosome) measuring instrument that is expected to enable extremely early diagnosis. The healthcare business is also a field that will have a strong impact on the super-aging society, and, as such, we are striving to develop and launch products that meet the needs of medical professionals.

Market Launch of High-Resolution Medical Image Display Monitor

In 2017, JVCKENWOOD launched two models of 21.3-inch color LCD monitors under the i3 Series — CL-S200 (2 megapixels) and CL-S300 (3 megapixels) — in a new lineup of medical image displays. In June 2019, we released two additional models (5 megapixels): CL-S500, a 21.3-inch color LCD monitor and MS-S500, a 21.3-inch monochrome LCD monitor.


CL-S500 is a medical image display monitor that achieves both an accurate reproduction of monochrome images and a multi modality diagnostic reading environment that makes use of various medical images in color, including those from ultrasound, endoscope, and pathology tests. In particular, our unique Dynamic Gamma* function automatically distinguishes between monochrome and color images that are intermixed on the screen, in units of pixels. Thus, each image is displayed in the optimal tonal scale in real time. This contributes to improving efficiency in the image interpretation process by enhancing the readability of color images.

* Patent No. 6277984

With enhanced brightness of the LCD panel, MS-S500 comes with 1,000 cd/m2 calibration. In addition, a contrast ratio of 2000:1 has increased the number of perceptual grayscale steps to improve contrast resolution significantly compared with that of conventional models (comparison made by JVCKENWOOD). This has led to improving the visibility of micro-calcifications, tumors and structures, enhancing the sense of depth of the lesioned part in highly dense breast images, and thereby contributing to providing more efficient diagnostic reading.


Going Forward, we will continue to work on enhancing the lineup of further advanced i3 Series monitors and strive to provide optimal image interpretation environments for everyone involved in interpreting radiograms.

Mammography/tomosynthesis image display monitors: CL-S500/MS-S500

i3 Series
Dynamic Gamma function image

Visual comparison based on difference in contrast ratio (image)

ExoCounter that Supports Very Early Diagnosis of Diseases

As the world braces for the challenges of an aging society and the increased burden of medical costs, increasing importance is placed on pre-disease diagnosis stemming from the advancement in preventative medicine, and even more on very early diagnosis performed during the disease-free period through exams conducted at the cell and particle level.

We combined our properties in optical disk and nanobead*3 technologies to develop an exosome measurement system called ExoCounter that detects and measures each antigen-specific exosome in body fluids. Exosome is a vesicle particle measuring approximately 50–100 nm in diameter that is released from a variety of types of cells, and exists in body fluids such as blood, saliva, and urine. Exosomes are embedded with various substances including protein, mRNA*1, and micro RNA*2, and as of recent years these substances are expected to serve as biomarkers for various diseases including cancer. The ExoCounter contributes to the early detection of cancer by using blood, since blood tests place a low physical burden on examinees.


Since 2016, JVCKENWOOD has been working with SYSMEX CORPORATION for the joint development of ExoCounter system. We collaborate with various research organizations in conducting research and development with the aim of improving the quality of diagnoses and treatment of illnesses. Furthermore, our joint research conducted together with the Keio University School of Medicine and the Tokyo Medical University discovered for the first time that breast cancer and ovarian cancer patients have a statistically and significantly high number of cancer-specific exosomes in their serum. (See the news release dated July 19, 2018.) The results of this research are expected to help further development of new cancer diagnosis and treatment methods using exosomes, and help advance studies on cancer.

In 2019, we launched joint research with Oxford University (U.K.) and Sysmex R&D Center Europe GmbH, an overseas subsidiary of SYSMEX CORPORATION, in an aim to establish a system for predicting the onset of pre-eclampsia using exosomes ( See the news release dated June 18, 2019.)

Based on the results of the above research activities, JVCKENWOOD will continue to work toward answering the needs of society by providing products that will realize very early diagnosis of illnesses and enable treatment that is suitable for each individual patient.


*1 mRNA : mRNA (messenger RNA) is RNA that copies and conveys genetic information on protein synthesis from the DNA sequence.

*2 microRNA : microRNA (miRNA) is one chain of an RNA molecule about the length of 20 nucleotides, and is associated with performing the role of controlling the expression of numerous genes and proteins. In recent years, miRNA found in exosomes has been attracting attention as being effective in the diagnosis of diseases because it remains stable and will not be degraded by enzymes in the blood, and because it changes dramatically in terms of amount and type depending on the type of disease and its level of development.

*3 Nanobead : Nanobeads are beads measured on the scale of nanometers (nm, one-millionth of a millimeter). The nanobeads used in this technology have a diameter of about 200 nm. The surface of the beads is solid-phased with an antibody that docks with substances on the exosomes, which enables the detection of specific exosomes that are being looked for.



Assay kit

Please see the link provided below for further details.